This brief historical review on neuroscience in Norway shows a comparatively high research activity with many important results. The Norwegian zoologist Fridtjof Nansen, who later became a famous Arctic explorer, was the first to formulate the neuron doctrine. 'The Oslo School of Neuroanatomy' contributed enormously to the understanding of the detailed anatomy and chemistry of the central nervous system. Norwegian neurophysiologists made important findings from studies of hippocampus including the inhibitory basket cell, the LTP phenomenon and the 'hippocampal-slice-technique'. In clinical neuroscience the description of Refsum's disease and studies of myasthenia gravis and multiple sclerosis have been of particular importance. Two of 13 centres of excellence in Norway selected in 2003 were from neuroscience, and The Norwegian Research Council has its own programme for neuroscience. The Norwegian Neurological Association arranges annual meetings to promote interest in neurological research.
There is a strong tradition of neuroscience in Norway, and Norwegian neurologists have been actively involved in developing partnerships between all those who recognize the importance of the brain and of brain diseases. It was therefore unsurprising that Norwegian neurologists took the initiative in establishing the Norwegian Brain Council (NBC). NBC was founded in 2007 and now comprises 27 organizations and institutions. It includes all those who work with brain research and brain diseases in Norway, as well as all relevant user organizations. Industries and businesses that are related to brain disease may be partners, but do not have full membership. The main mission of NBC is to provide information about the brain and brain diseases for both lay people and public authorities, including politicians, and to promote better treatment for patients with brain diseases and more research in neuroscience. The council has firm ties to the European Brain Council (EBC). NBC plans to follow the initiative taken by EBC in organizing a 'Month of the Brain' in 2013 and a 'Year of the Brain' in 2014. These initiatives could provide an impetus for greater focus on brain diseases, which is essential in order to meet the considerable challenges that are posed by brain diseases in the years to come.
12 December 2007 in Progress in Neurotherapeutics and Neuropsychopharmacology
Background: Anti-epileptic drugs (AEDs) are associated with cognitive side effects. Doubt exists regarding the degree of cognitive effects primarily related to problems with design and methodology in many studies. The aim of the reported study was to assess the effect of AED withdrawal in patients on monotherapy using computerised measures of attention, reaction time and speed of information processing. Methods: One hundred and fifty patients seizure free >2 years on drug monotherapy went through a randomised, double blind, placebo controlled study. All patients were included for 12 months or until seizure relapse. Cognitive function was assessed with the California Computerized Assessment Package at baseline and 7 months after withdrawal. Results: The major finding was that discontinuation of major AEDs significantly improved performance on tests that require complex cognitive processing under time pressure. The difference in speed of cognitive processing between the withdrawal and non-withdrawal groups was between 24 and 43 ms. No significant difference emerged between the groups on simple tasks of attention and reaction time. Most of the patients in the study were treated with carbamazepine and valproate. The outcome of carbamazepine withdrawal was similar to the outcome for the total study population while discontinuation of valproate only revealed a non-significant tendency in the same direction. Interpretation: The results suggest that seizure-free epilepsy patients on monotherapy can obtain improvement in speeded cognitive processing if they withdraw anti-epileptic treatment.